Across TCGA pan-cancer cohorts, IGHV3-20 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGHV3-20 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher IGHV3-20 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IGHV3-20 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, LUAD, and PDAC are the cancer types where IGHV3-20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.754	0.603	.011	11	view →
LUAD	DFS	Median	All	0.847	0.964	.029	6	view →
PDAC	OS	Quartile	II,III,IV	0.942	0.403	.017	6	view →
UCEC	OS	Quartile	All	1.000	0.709	.048	2	view →
CCRCC	OS	Quartile	All	1.000	0.846	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGHV3-20 tumor-vs-normal RNA expression · all IGHV3-20 data types